Figure 5.
![Impact of genomic alterations on clinical outcome. (A) A heat map showing all the genomic alterations associated with progression after CAR-19 cell therapy. (B) Kaplan-Meier plot for PFS, comparing patients with DLBCL with and without any significant genomic drivers (ie, APOBEC mutational activity, double minutes, deletion 3p21.31 [RHOA], SBS18, and chromothripsis; n = 47). (C) Cox multivariate model between the significant clinical and genomic features for PFS.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/140/5/10.1182_blood.2021015008/6/bloodbld2021015008f5.png?Expires=1725146387&Signature=jySFm4wQVYx9bOZ3VZltf1yt0g~8waeesCgvFsqhxknmck~oumY5NouOW9PkEwqbUNe-TQQGH0gEXH~U4fN6s3oaa3C5M2dI7EKODzTJuwc~Y4mzgerBPZK4PCduSQC1Rm10NG6FxtG8xzO5jOs~Y~wlP~~Hy1-jvxBSJL~U10XWtlKl6km9Xh9ucBV-cFX1r1vEnisYap-dREJDHMeexBYevNq5hzZhV8NAHN-nE7YjLGzr4aq~2z7~dK2EIaal8yMzfkBsQKmVeA23qx~Ll9-i6N~75ms-paU2t0AyoaFXc5kGYB-xowMyLy52ZNmcSjCWeyOF59MibkADX7Nf2g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Impact of genomic alterations on clinical outcome. (A) A heat map showing all the genomic alterations associated with progression after CAR-19 cell therapy. (B) Kaplan-Meier plot for PFS, comparing patients with DLBCL with and without any significant genomic drivers (ie, APOBEC mutational activity, double minutes, deletion 3p21.31 [RHOA], SBS18, and chromothripsis; n = 47). (C) Cox multivariate model between the significant clinical and genomic features for PFS.